4.8 Article

Rebalancing TGF-β/Smad7 signaling via Compound kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis

期刊

出版社

JOHN WILEY & SONS LTD
DOI: 10.1002/ctm2.410

关键词

Compound kushen injection; hepatocellular carcinoma; liver fibrosis; TGF-beta/Smad signaling; traditional chinese medicine

资金

  1. National Key R&D Program of China [2018YFC2000700]
  2. National Science and Technology Major Project [2017ZX09101002-002-005]
  3. National Nature Science Foundation [82030099, 81630086, 81972820, 81973078]
  4. Shanghai Public Health System Construction Three-Year Action Plan [GWV-10.1-XK15]
  5. Major Science and Technology Innovation Program of Shanghai Municipal Education Commission [2019-01-07-00-01-E00059]
  6. Shanghai Municipal Human Resources and Social Security Bureau [2018060]
  7. Innovative Research Team of High-Level Local Universities in Shanghai
  8. Shanghai Pujiang Talent Program

向作者/读者索取更多资源

Through meta-analysis and preclinical experiments, this study revealed that Compound kushen injection (CKI) has anti-fibrotic and anti-hepatocarcinogenesis effects by rebalancing TGF-beta/Smad7 signaling to protect against liver fibrosis and hepatocarcinogenesis in both preclinical and clinical studies. CKI could be a potential candidate for the treatment of hepatic fibrosis and related oncogenesis.
Background: Liver fibrosis and fibrosis-related hepatocarcinogenesis are a rising cause for morbidity and death worldwide. Although transforming growth factor-beta (TGF-beta) is a critical mediator of chronic liver fibrosis, targeting TGF-beta isoforms and receptors lead to unacceptable side effect. This study was designed to explore the antifibrotic effect of Compound kushen injection (CKI), an approved traditional Chinese medicine formula, via a therapeutic strategy of rebalancing TGF-beta/Smad7 signaling. Methods: A meta-analysis was performed to evaluate CKI intervention on viral hepatitis-induced fibrosis or cirrhosis in clinical randomized controlled trials (RCTs). Mice were given carbon tetrachloride (CCl4) injection or methionine-choline deficient (MCD) diet to induce liver fibrosis, followed by CKI treatment. We examined the expression of TGF-beta/Smad signaling and typical fibrosis-related genes in hepatic stellate cells (HSCs) and fibrotic liver tissues by qRT-PCR, Western blotting, RNA-seq, immunofluorescence, and immunohistochemistry. Results: Based on meta-analysis results, CKI improved the liver function and relieved liver fibrosis among patients. In our preclinical studies by using two mouse models, CKI treatment demonstrated promising antifibrotic effects and postponed hepatocarcinogenesis with improved liver function and histopathologic features. Mechanistically, we found that CKI inhibited HSCs activation by stabilizing the interaction of Smad7/TGF-beta R1 to rebalance Smad2/Smad3 signaling, and subsequently decreased the extracellular matrix formation. Importantly, Smad7 depletion abolished the antifibrotic effect of CKI in vivo and in vitro. Moreover, matrine, oxymatrine, sophocarpine, and oxysophocarpine were identified as material basis responsible for the antifibrosis effect of CKI. Conclusions: Our results unveil the approach of CKI in rebalancing TGF-beta/Smad7 signaling in HSCs to protect against hepatic fibrosis and hepatocarcinogenesis in both preclinical and clinical studies. Our study suggests that CKI can be a candidate for treatment of hepatic fibrosis and related oncogenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据